Axsome Therapeutics (AXSM) Income from Continuing Operations (2015 - 2026)

Axsome Therapeutics has disclosed Income from Continuing Operations across 12 years of filings, most recently posting 64542000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 64542000.0, down 8.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 188293000.0 (up 32.33% YoY), and the FY2025 annual result was 183204000.0, up 36.21% from the prior year.
• Income from Continuing Operations came in at 64542000.0 for Q1 2026 at Axsome Therapeutics, down from 28589000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 11238000.0 in Q1 2023 to a low of 98651000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 61241000.0 (2022), against an average of 56548882.35.
• Across the five-year window, Income from Continuing Operations surged 71.64% in 2023 and slumped 508.27% in 2024, its largest moves.
• Axsome Therapeutics' Income from Continuing Operations stood at 61241000.0 in 2022, then slumped by 61.09% to 98651000.0 in 2023, then rose by 24.06% to 74912000.0 in 2024, then surged by 61.84% to 28589000.0 in 2025, then sank by 125.76% to 64542000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 64542000.0 (Q1 2026), 28589000.0 (Q4 2025), and 47229000.0 (Q3 2025), per Business Quant data.